Navigation Links
VeroScience Late-Breaking Abstract on Cycloset (A Quick Release,Formulation of Bromocriptine Mesylate) Accepted for Poster,Presentation at American Diabetes Association 67th Scientific,Sessions

TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC, a privately held biotechnology and healthcare product development company, announced today that its late-breaking abstract has been accepted as a poster presentation at the 67th Scientific Sessions of the American Diabetes Association in Chicago, Ill. The abstract, entitled, "Effects of Timed Cycloset(TM) (A Quick Release Formulation of Bromocriptine Mesylate) Administration of Safety, Cardiovascular Event Rate, and Glycemic Control in Subjects with Type 2 Diabetes Receiving Diet, Oral Hypoglycemic, and/or Insulin Treatment Regimens," will be included in the category of Clinical Therapeutics/New Technology - Pharmacologic Treatment of Diabetes or its Complications and displayed Saturday, Sunday and Monday, June 23-25, in the General Poster Session in the Exhibit Hall.

VeroScience is also sponsoring a corporate symposium supported by its commercialization partner for Cycloset(TM), S2 Therapeutics, Inc., that will be held in conjunction with the American Diabetes Association's 67th Scientific Sessions. The symposium, entitled "Evolution, Hypothalamic Dopamine Neurochemistry, and Developing New Therapies for Insulin Resistance Syndrome and Type 2 Diabetes," will be held on Sunday, June 24th from 5:30-7:45 AM at the Hyatt Regency Chicago, Grand F/D South. Registration and breakfast are from 5:00-5:30 AM or you can register in advance at www.veroscience.com/ada2007registration.

Cycloset(TM), an oral, quick-release formulation of bromocriptine is a centrally-acting dopamine D2 receptor agonist that is being studied as a potential therapy in the treatment of type 2 diabetes.

VeroScience is a privately held biotechnology and healthcare product development company with main offices and laboratories in Tiverton, RI. VeroScience has a large patent portfolio tha t supports its preclinical and clinical development programs and product pipeline in the areas of metabolism, immunology, reproduction, and oncology. VeroScience leverages its intellectual property and products in out-licensing and collaborative arrangements with appropriate industry partners.

S2 Therapeutics, a privately held specialty pharmaceutical company headquartered in Bristol, TN, is the commercialization partner for Cycloset(TM) and is the holder of an exclusive global license for the manufacture, marketing and distribution of Cycloset(TM). S2 seeks opportunities in the pharmaceutical industry through in-licensing arrangements and acquisitions of novel branded prescription pharmaceutical products.


    Contacts:

    Feinstein Kean Healthcare

    Christine Cramer, 617-761-6736

    
 
christine.cramer@fkhealth.com

CONTACT: Christine Cramer of Feinstein Kean Healthcare, +1-617-761-6736,, for VeroScience, LLC christine.cramer@fkhealth.com

Web site: http://www.veroscience.com/ada2007registration/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
2. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
3. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
4. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
5. OXiGENE Abstracts Published in ASCO Program
6. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
7. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
8. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
9. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
10. Pro-Pharmaceuticals to Present Abstract at the International Society of Oncodevelopmental Biology and Medicine Conference
11. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 Research and Markets has announced the ... their offering. ... R&D Drug Pipeline Database: 1-Year ... Drug Pipeline Database provides 24/7 online access to information about more ... and on investigational drug candidates in research & development. ...
(Date:12/2/2016)... 2016 The U.S. Food and Drug Administration ... reduce the risk of cardiovascular death in adult patients ... "Cardiovascular disease is a leading cause of ... Jean-Marc Guettier , M.D., C.M., director of the ... for Drug Evaluation and Research. "Availability of antidiabetes therapies ...
(Date:12/2/2016)... December 2, 2016 - bioLytical lanza el INSTI HIV ... la OMS     Continue Reading ... ... , , bioLytical ... anunciado hoy que está expandiendo el lanzamiento de su INSTI HIV Self Test ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report ... parents report speaking with their child about sex related topics, less than 60 percent ... is proud to announce the launch of its second edition of the “Sexual Wellness” ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a class-leading ... LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep ... disposal. The new version is a faster and a more efficient product, allowing ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, ... and the first company to offer robotic imaging to veterinary medicine is sponsoring ... # 941 for the American Association of Equine Practitioners 62nd Annual Convention from ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Rijuven Corp launches ... overall health, day and night. No other wearable health technology on the market can ... wanted to give poeple more meaningful insights about their health than the usual heart ...
(Date:12/2/2016)... ... , ... "Pro3rd Accents Volume 2 is a set of 30 accented lower ... just a few clicks of the mouse," said Christina Austin - CEO of Pixel ... from various styles with accented animations, rigid boxes, simplistic lines, and more. In Addition, ...
Breaking Medicine News(10 mins):